Latest Articles and Analysis

Q1 2022 assessment of HCV treatment access in ADAPs and Medicaid with DAA coverage and harm reduction data.

Flurona co-infections highlight information challenges amid pandemic fatigue and misinformation.

CDC updates STI treatment guidelines; ACIP recommends universal adult HBV vaccination and HPV catch-up.

CANN announces 2022 organizational changes including rebranding and launching the 340B Action Center.

CANN reflects on 2021 advocacy spanning 340B drug pricing, HIV, hepatitis C, and substance use disorder policy.

FDA reclassifies HCV testing to reduce regulatory burden and enable new test makers to enter market.

New CANN leadership reflects on mentorship and maintaining advocacy legacy following Bill Arnold's passing.

Final installment addressing 340B reform needs: transparency, accountability, and contract pharmacy concerns.

Analyzes the role of contract pharmacies and intermediaries in 340B drug distribution and patient access.

Examines how 340B program expansion correlates with declining hospital charity care for vulnerable patients.

Explores accountability mechanisms in the 340B program and oversight requirements for patient protection.

Explains why transparency in 340B operations is critical for program integrity and patient access.

Q4 2021 Watch covering HCV drug formulary updates, ADAP and Medicaid changes, and pandemic impact on care.

Introduces the 340B Drug Discount Program: its history, purpose, and significance for medication access.

Payers restrict HCV treatment through utilization management; patient assistance programs fill the critical gap.

Global Fund report shows COVID-19 reduced HIV/HCV program efficacy while South Africa tripled ART coverage.

Analyzes CMS marketplace rule changes and Medicaid expansion risks as pandemic emergency declarations end.

31,000 Veterans with HIV face unique barriers including comorbidities and HCV rates 3x the general population.

Analyzes Biden health policy priorities including drug pricing reform and Medicare expansion.

Analysis of hepatitis B vaccine efficacy and revaccination protocols for people living with HIV.